The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism

The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism

Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respecti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European thyroid journal 2015-01, Vol.4 (3), p.149-163
Hauptverfasser: Biondi, Bernadette, Bartalena, Luigi, Cooper, David S., Hegedüs, Laszlo, Laurberg, Peter, Kahaly, George J.
Format: Artikel
Sprache:eng
Schlagworte:
Guidelines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 163
container_issue 3
container_start_page 149
container_title European thyroid journal
container_volume 4
creator Biondi, Bernadette
Bartalena, Luigi
Cooper, David S.
Hegedüs, Laszlo
Laurberg, Peter
Kahaly, George J.
description Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels
doi_str_mv 10.1159/000438750
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000438750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1732597131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-d02c30714b0e3097baaa2adb6ababd1ced3662a1799b20244f013cf88f81cdd03</originalsourceid><addsrcrecordid>eNpVkU1rHDEMhk1paEKaQ-8l-NgctpXt-bwUQrJJCoEcuj0bja3ZdTtjb-yZwv77OOxmaU-S0KNXEi9jnwR8FaJsvwFAoZq6hHfsTEpVLqAB-f4trwo4ZRcp_c4YNFUl6vYDO5VVWTZSyTM2rzbEJYiSL-cYtoSerza7GJzl1ykF43BywfP72VkanKfEc3XrcO1Dcomjt3wVCaeR_MRDz5fehjX5MCf-c-5MHnEGB_6w21Kc9sIujR_ZSY9DootDPGe_7parm4fF49P9j5vrx4VRrZwWFqRRUIuiA1LQ1h0iSrRdhR12Vhiyqqok5p_aToIsih6EMn3T9I0w1oI6Z9_3utu5G8mafGTEQW-jGzHudECn_-94t9Hr8FcXlapLobLAl4NADM8zpUmPLhkaBvSUf9SiVrJsa6FERq_2qIkhpUj9cY0A_eqUPjqV2ct_7zqSb75k4PMe-INxTfEIHOZfAApjmUY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1732597131</pqid></control><display><type>article</type><title>The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Biondi, Bernadette ; Bartalena, Luigi ; Cooper, David S. ; Hegedüs, Laszlo ; Laurberg, Peter ; Kahaly, George J.</creator><creatorcontrib>Biondi, Bernadette ; Bartalena, Luigi ; Cooper, David S. ; Hegedüs, Laszlo ; Laurberg, Peter ; Kahaly, George J.</creatorcontrib><description>Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels &lt;0.1 mIU/l (grade 2 SHyper). Therefore, despite the absence of randomized prospective trials, there is evidence that treatment is indicated in patients older than 65 years with grade 2 SHyper to potentially avoid these serious cardiovascular events, fractures and the risk of progression to overt hyperthyroidism. Treatment could be considered in patients older than 65 years with TSH levels 0.1-0.39 mIU/l (grade 1 SHyper) because of their increased risk of atrial fibrillation, and might also be reasonable in younger (&lt;65 years) symptomatic patients with grade 2 SHyper because of the risk of progression, especially in the presence of symptoms and/or underlying risk factors or co-morbidity. Finally, the task force concluded that there are no data to support treating SHyper in younger asymptomatic patients with grade 1 SHyper. These patients should be followed without treatment due to the low risk of progression to overt hyperthyroidism and the weaker evidence for adverse health outcomes.</description><identifier>ISSN: 2235-0640</identifier><identifier>EISSN: 2235-0802</identifier><identifier>DOI: 10.1159/000438750</identifier><identifier>PMID: 26558232</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Guidelines</subject><ispartof>European thyroid journal, 2015-01, Vol.4 (3), p.149-163</ispartof><rights>2015 European Thyroid Association Published by S. Karger AG, Basel</rights><rights>Copyright © 2015 European Thyroid Association Published by S. Karger AG, Basel 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-d02c30714b0e3097baaa2adb6ababd1ced3662a1799b20244f013cf88f81cdd03</citedby><orcidid>0000-0001-8360-4464 ; 0000-0002-9691-7619</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637513/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637513/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26558232$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Biondi, Bernadette</creatorcontrib><creatorcontrib>Bartalena, Luigi</creatorcontrib><creatorcontrib>Cooper, David S.</creatorcontrib><creatorcontrib>Hegedüs, Laszlo</creatorcontrib><creatorcontrib>Laurberg, Peter</creatorcontrib><creatorcontrib>Kahaly, George J.</creatorcontrib><title>The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism</title><title>European thyroid journal</title><addtitle>Eur Thyroid J</addtitle><description>Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels &lt;0.1 mIU/l (grade 2 SHyper). Therefore, despite the absence of randomized prospective trials, there is evidence that treatment is indicated in patients older than 65 years with grade 2 SHyper to potentially avoid these serious cardiovascular events, fractures and the risk of progression to overt hyperthyroidism. Treatment could be considered in patients older than 65 years with TSH levels 0.1-0.39 mIU/l (grade 1 SHyper) because of their increased risk of atrial fibrillation, and might also be reasonable in younger (&lt;65 years) symptomatic patients with grade 2 SHyper because of the risk of progression, especially in the presence of symptoms and/or underlying risk factors or co-morbidity. Finally, the task force concluded that there are no data to support treating SHyper in younger asymptomatic patients with grade 1 SHyper. These patients should be followed without treatment due to the low risk of progression to overt hyperthyroidism and the weaker evidence for adverse health outcomes.</description><subject>Guidelines</subject><issn>2235-0640</issn><issn>2235-0802</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVkU1rHDEMhk1paEKaQ-8l-NgctpXt-bwUQrJJCoEcuj0bja3ZdTtjb-yZwv77OOxmaU-S0KNXEi9jnwR8FaJsvwFAoZq6hHfsTEpVLqAB-f4trwo4ZRcp_c4YNFUl6vYDO5VVWTZSyTM2rzbEJYiSL-cYtoSerza7GJzl1ykF43BywfP72VkanKfEc3XrcO1Dcomjt3wVCaeR_MRDz5fehjX5MCf-c-5MHnEGB_6w21Kc9sIujR_ZSY9DootDPGe_7parm4fF49P9j5vrx4VRrZwWFqRRUIuiA1LQ1h0iSrRdhR12Vhiyqqok5p_aToIsih6EMn3T9I0w1oI6Z9_3utu5G8mafGTEQW-jGzHudECn_-94t9Hr8FcXlapLobLAl4NADM8zpUmPLhkaBvSUf9SiVrJsa6FERq_2qIkhpUj9cY0A_eqUPjqV2ct_7zqSb75k4PMe-INxTfEIHOZfAApjmUY</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Biondi, Bernadette</creator><creator>Bartalena, Luigi</creator><creator>Cooper, David S.</creator><creator>Hegedüs, Laszlo</creator><creator>Laurberg, Peter</creator><creator>Kahaly, George J.</creator><general>S. Karger AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8360-4464</orcidid><orcidid>https://orcid.org/0000-0002-9691-7619</orcidid></search><sort><creationdate>20150101</creationdate><title>The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism</title><author>Biondi, Bernadette ; Bartalena, Luigi ; Cooper, David S. ; Hegedüs, Laszlo ; Laurberg, Peter ; Kahaly, George J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-d02c30714b0e3097baaa2adb6ababd1ced3662a1799b20244f013cf88f81cdd03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Guidelines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Biondi, Bernadette</creatorcontrib><creatorcontrib>Bartalena, Luigi</creatorcontrib><creatorcontrib>Cooper, David S.</creatorcontrib><creatorcontrib>Hegedüs, Laszlo</creatorcontrib><creatorcontrib>Laurberg, Peter</creatorcontrib><creatorcontrib>Kahaly, George J.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European thyroid journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Biondi, Bernadette</au><au>Bartalena, Luigi</au><au>Cooper, David S.</au><au>Hegedüs, Laszlo</au><au>Laurberg, Peter</au><au>Kahaly, George J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism</atitle><jtitle>European thyroid journal</jtitle><addtitle>Eur Thyroid J</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>4</volume><issue>3</issue><spage>149</spage><epage>163</epage><pages>149-163</pages><issn>2235-0640</issn><eissn>2235-0802</eissn><abstract>Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels &lt;0.1 mIU/l (grade 2 SHyper). Therefore, despite the absence of randomized prospective trials, there is evidence that treatment is indicated in patients older than 65 years with grade 2 SHyper to potentially avoid these serious cardiovascular events, fractures and the risk of progression to overt hyperthyroidism. Treatment could be considered in patients older than 65 years with TSH levels 0.1-0.39 mIU/l (grade 1 SHyper) because of their increased risk of atrial fibrillation, and might also be reasonable in younger (&lt;65 years) symptomatic patients with grade 2 SHyper because of the risk of progression, especially in the presence of symptoms and/or underlying risk factors or co-morbidity. Finally, the task force concluded that there are no data to support treating SHyper in younger asymptomatic patients with grade 1 SHyper. These patients should be followed without treatment due to the low risk of progression to overt hyperthyroidism and the weaker evidence for adverse health outcomes.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>26558232</pmid><doi>10.1159/000438750</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-8360-4464</orcidid><orcidid>https://orcid.org/0000-0002-9691-7619</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2235-0640
ispartof European thyroid journal, 2015-01, Vol.4 (3), p.149-163
issn 2235-0640
2235-0802
language eng
recordid cdi_crossref_primary_10_1159_000438750
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Guidelines
title The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A13%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%202015%20European%20Thyroid%20Association%20Guidelines%20on%20Diagnosis%20and%20Treatment%20of%20Endogenous%20Subclinical%20Hyperthyroidism&rft.jtitle=European%20thyroid%20journal&rft.au=Biondi,%20Bernadette&rft.date=2015-01-01&rft.volume=4&rft.issue=3&rft.spage=149&rft.epage=163&rft.pages=149-163&rft.issn=2235-0640&rft.eissn=2235-0802&rft_id=info:doi/10.1159/000438750&rft_dat=%3Cproquest_cross%3E1732597131%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1732597131&rft_id=info:pmid/26558232&rfr_iscdi=true